Table 2.
Characteristics of study population based on their initial exposure in the USA
| Unexposed | Tamoxifen | AI | Total | |
| N | 4667 (100) | 2286 (100) | 15 074 (100) | 22 027 (100) |
| Age at index date (years) | ||||
| 66–74 | 1538 (33) | 897 (39.2) | 7505 (49.8) | 9940 (45.1) |
| 75–84 | 1937 (41.5) | 994 (43.5) | 5894 (39.1) | 8825 (40.1) |
| 85+ | 1192 (25.5) | 395 (17.3) | 1675 (11.1) | 3262 (14.8) |
| Median (IQR) | 79 (73–85) | 77 (72–83) | 75 (71–81) | 76 (71–82) |
| Ethnicity* | ||||
| White | 4002 (85.8) | 2028 (88.7) | 12 782 (84.8) | 18 812 (85.4) |
| Black | 360 (7.7) | 102 (4.5) | 1099 (7.3) | 1561 (7.1) |
| Other | 93 (2) | 47 (2.1) | 335 (2.2) | 475 (2.2) |
| Asian | 123 (2.6) | 68 (3) | 498 (3.3) | 689 (3.1) |
| Hispanic | – | – | – | 397 (1.8) |
| Native American | – | – | – | 52 (.2) |
| Missing | – | – | – | 41 (.2) |
| SEER region | ||||
| North East | 760 (16.3) | 283 (12.4) | 3320 (22) | 4363 (19.8) |
| South | 1023 (21.9) | 605 (26.5) | 3778 (25.1) | 5406 (24.5) |
| North Central | 695 (14.9) | 448 (19.6) | 1761 (11.7) | 2904 (13.2) |
| West | 2157 (46.2) | 939 (41.1) | 6130 (40.7) | 9226 (41.9) |
| Missing | 32 (.7) | 11 (.5) | 85 (.6) | 128 (.6) |
| Year of breast cancer | ||||
| 2008–2009 | 1678 (36) | 1231 (53.8) | 6609 (43.8) | 10 247 (46.5) |
| 2010–2011 | 1473 (31.6) | 701 (30.7) | 5019 (33.3) | 7193 (32.7) |
| 2012–2013 | 1516 (32.5) | 722 (31.6) | 5840 (38.7) | 8078 (36.7) |
| Stage of breast cancer | ||||
| Stage I | 3034 (65) | 1486 (65) | 8379 (55.6) | 12 899 (58.6) |
| Stage II | 1275 (27.3) | 660 (28.9) | 5267 (34.9) | 7202 (32.7) |
| Stage III | 358 (7.7) | 140 (6.1) | 1428 (9.5) | 1926 (8.7) |
| Grade of breast cancer | ||||
| 1 | 1522 (32.6) | 765 (33.5) | 4273 (28.3) | 6560 (29.8) |
| 2 | 2071 (44.4) | 1109 (48.5) | 7350 (48.8) | 10 530 (47.8) |
| 3 | 853 (18.3) | 324 (14.2) | 2810 (18.6) | 3987 (18.1) |
| Missing | 221 (4.7) | 88 (3.8) | 641 (4.3) | 950 (4.3) |
| Cancer treatments | ||||
| Taxane | 570 (12.2) | 162 (7.1) | 2415 (16) | 3147 (14.3) |
| Anthracyclines | 259 (5.5) | 68 (3) | 820 (5.4) | 1147 (5.2) |
| Trastuzumab | 226 (4.8) | 39 (1.7) | 687 (4.6) | 952 (4.3) |
| Other treatment | 753 (16.1) | 244 (10.7) | 2992 (19.8) | 3989 (18.1) |
| Comorbidities | ||||
| RA | 185 (4) | 103 (4.5) | 547 (3.6) | 835 (3.8) |
| CKD | 383 (8.2) | 155 (6.8) | 1113 (7.4) | 1651 (7.5) |
| Hypertension | 3426 (73.4) | 1612 (70.5) | 11 113 (73.7) | 16 151 (73.3) |
| Diabetes | 1313 (28.1) | 598 (26.2) | 4545 (30.2) | 6456 (29.3) |
| CVD-related treatment before index | ||||
| Statins | 1778 (38.1) | 948 (41.5) | 6988 (46.4) | 9714 (44.1) |
| Hypertensives | 169 (3.6) | 83 (3.6) | 577 (3.8) | 829 (3.8) |
| ACEi | 962 (20.6) | 477 (20.9) | 3251 (21.6) | 4690 (21.3) |
| CCB | 850 (18.2) | 364 (15.9) | 2696 (17.9) | 3910 (17.8) |
| ARB | 593 (12.7) | 255 (11.2) | 2063 (13.7) | 2911 (13.2) |
| Past CVD | ||||
| Non-venous CVD | 2989 (64) | 1281 (56) | 8896 (59) | 13 166 (59.8) |
| VTE | 162 (3.5) | 31 (1.4) | 385 (2.6) | 578 (2.6) |
*Cell numbers within ethnicity suppressed due to some cells containing numbers <11.
ACEi, Angiotensin-converting-enzyme inhibitors; AI, aromatase inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker; CKD, Chronic kidney disease; CVD, cardiovascular disease; RA, Rheumatoid arthritis; SEER, Surveillance, Epidemiology, and End Results; VTE, venous thromboembolism.